Partner Headlines - BMY

  1. Bristol-Myers: Absolute Valuation Model versus Relative Valuation ...

    GuruFocus
  2. Bristol-Myers Drug Gets OK

    IBD
  3. Markets Little Changed In Low Volume And Slow News Ahead Of Long ...

    Benzinga
  4. Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers ...

    Benzinga
  5. Bristol-Myers Hepatitis C Therapy Approved in EU

    IBD
  6. US Stock Futures Edge Higher Ahead Of Tiffany Earnings

    Benzinga
  7. Merck, Pfizer Combining Drugs In Lung Cancer Study

    IBD
  8. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  9. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  10. Drugmaker AstraZeneca Returns To Growth

    IBD
  11. The Stocks Already in Correction Mode

    FoxBusiness
  12. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  13. Bristol-Myers surprises Street

    IBD
  14. Thursday Morning Earnings Reports

    Benzinga
  15. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  16. Earnings Scheduled For July 24, 2014

    Benzinga
  17. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  18. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical ...

    Benzinga
  19. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  20. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  21. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  22. Bristol seeks cancer drug nod

    IBD
  23. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  24. Japan approves BMY regimen

    IBD
  25. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  26. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  27. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  28. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  29. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  30. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target ...

    Benzinga
  31. Benzinga's Top Downgrades

    Benzinga
  32. Ex-Dividends For July 1, 2014

    Benzinga
  33. Pfizer and others get EU nods

    IBD
  34. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  35. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  36. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  37. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza ...

    Benzinga
  38. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  39. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  40. BRISTOL-MYERS SQUIBB

    IBD
  41. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab ...

    Benzinga
  42. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  43. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  44. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  45. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  46. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  47. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  48. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  49. Bristol, Merck Q1 sales soft

    IBD
  50. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  51. ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, ...

    Benzinga
  52. UPDATE: Bristol-Myers Posts Higher Q1 Profit

    Benzinga
  53. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  54. Bristol-Myers Squibb Acquires iPierian for $175M, Potential Milestone ...

    Benzinga
  55. Earnings Scheduled For April 29, 2014

    Benzinga
  56. Stocks To Watch For April 29, 2014

    Benzinga
  57. Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump

    IBD
  58. Earnings Expectations For The Week Of April 28: Big Oil, Big ...

    Benzinga
  59. Benzinga Weekly Preview: Earnings Season Continues As Biotech ...

    Benzinga
  60. Week Ahead: April Jobs Report, FOMC Meeting and Earnings

    FoxBusiness
  61. Pfizer, AstraZeneca Rise On Report Of Merger Talks

    IBD
  62. UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose ...

    Benzinga
  63. Investors: Brace for a Turbulent Second Quarter

    FoxBusiness
  64. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  65. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  66. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  67. Novo Nordisk Upgraded to 'Buy'

    FoxBusiness
  68. Abbvie Inc. (ABBV) Dividend Stock Analysis

    GuruFocus
  69. Gilead's HCV Challengers Near The Starting Gate

    IBD
  70. Gilead's HCV Challengers Near The Starting Gate

    IBD
  71. Abbott Capturing Incremental Market Share

    GuruFocus
  72. US Stock Futures Jump Ahead Of Economic Data

    Benzinga
  73. Pfizer Breast-Cancer Drug To Show If It's For Real

    IBD
  74. Arrowhead Surges As Analysts Laud Hepatitis B Drug

    IBD
  75. Bristol Moving Ahead With Lung-Cancer Drug Combo

    IBD
  76. Bristol-Myers Squibb's

    IBD
  77. Pfizer Gets Good News For Pneumonia, Bone-Thinner Drugs

    IBD
  78. Market Wrap For February 24: Markets Showing Strength To Start ...

    Benzinga
  79. FDA Gives Bristol-Myers' Hepatitis Drug 'Breakthrough' Designation

    FoxBusiness
  80. Actavis, Forest In $25 Bil Deal

    IBD
  81. Actavis' Buyout Of Forest Creating Spec Pharma Giant

    IBD
  82. Vanguard Health Care Fund's Top Five

    GuruFocus
  83. UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on ...

    Benzinga
  84. Actavis, Valeant, Jazz: New Roles For Specialty Pharma

    IBD
  85. Investors Brace for Bear Market

    FoxBusiness
  86. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD
  87. #PreMarket Primer: Monday, January 27: Markets Open The Week ...

    Benzinga
  88. Bristol-Myers Int'l Sales Soar

    IBD
  89. Top Earnings-Related Movers for Week of Jan. 20th

    Benzinga
  90. Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

    Benzinga
  91. Bristol Q4 Beats, But Nivolumab Still Worries Market

    IBD
  92. Stocks Open Sharply Lower; Kansas City Southern Collapses

    IBD
  93. Stock Futures Down, Off Lows; Microsoft And Juniper Climb

    IBD
  94. Bristol-Myers 4Q Earnings Beat the Street

    FoxBusiness
  95. #PreMarket Primer: Friday, January 24: Growth Fears Drag Down ...

    Benzinga
  96. Earnings Scheduled For January 24, 2014

    Benzinga
  97. Stocks To Watch For January 24, 2014

    Benzinga
  98. Cancer drug result in question

    IBD
  99. Bristol-Myers' New Nivolumab Trial Sparks Worries

    IBD
  100. Growth Fund Of The Year: Stock Picks

    YCharts
Trading Center